The initial success of the copyright undeniably transformed the medication landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. Despite early returns were substantial, the end of patents and the appearance of less expensive alternatives have weakened market share. Consequently, a thorough ev